NCT02930655: A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease |
|
|
| Completed | 1b | 14 | Europe | Lucerastat, ACT-434964, Enzyme replacement therapy (ERT), Fabrazyme, Replagal | Idorsia Pharmaceuticals Ltd. | Fabry Disease | 02/16 | 02/16 | | |
NCT00357786: An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease |
|
|
| Completed | 1 | 3 | US | Replagal agalsidase alfa, Replagal | National Institute of Neurological Disorders and Stroke (NINDS) | Fabry Disease | 12/08 | | | |